GVHD-derived plasma as a priming strategy of mesenchymal stem cells

Background: Mesenchymal stem cell (MSC) therapy is an important alternative for GVHD treatment, but a third of patients fail to respond to such therapy. Therefore, strategies to enhance the immunosuppressive potential of MSCs constitute an active area of investigation. Here, we proposed an innovat...

Full description

Main Authors: Carvalho, Amandda Évelin Silva, Rodrigues, Leane Perim, Schiavinato, Josiane Lilian, Alborghetti, Marcos Rodrigo, Bettarello, Gustavo, Simões, Belinda Pinto, Neves, Francisco de Assis Rocha, Panepucci, Rodrigo Alexandre, Carvalho, Juliana Lott de, Araujo, Felipe Saldanha de
Format: Artigo
Language: Inglês
Published: BMC 2020
Subjects:
Online Access: https://repositorio.unb.br/handle/10482/39539
https://doi.org/10.1186/s13287-020-01659-x
Tags: Add Tag
No Tags, Be the first to tag this record!
id ir-10482-39539
recordtype dspace
spelling ir-10482-395392020-10-13T18:11:07Z GVHD-derived plasma as a priming strategy of mesenchymal stem cells Carvalho, Amandda Évelin Silva Rodrigues, Leane Perim Schiavinato, Josiane Lilian Alborghetti, Marcos Rodrigo Bettarello, Gustavo Simões, Belinda Pinto Neves, Francisco de Assis Rocha Panepucci, Rodrigo Alexandre Carvalho, Juliana Lott de Araujo, Felipe Saldanha de Células-tronco mesenquimais Linfócitos Doença do enxerto contra hospedeiro Imunomodulação Background: Mesenchymal stem cell (MSC) therapy is an important alternative for GVHD treatment, but a third of patients fail to respond to such therapy. Therefore, strategies to enhance the immunosuppressive potential of MSCs constitute an active area of investigation. Here, we proposed an innovative priming strategy based on the plasma obtained from GVHD patients and tested whether this approach could enhance the immunosuppressive capacity of MSCs. Methods: We obtained the plasma from healthy as well as acute (aGVHD) and chronic (cGVHD) GVHD donors. Plasma samples were characterized according to the TNF-α, IFN-γ, IL-10, IL-1β, IL-12p40, and IL-15 cytokine levels. The MSCs primed with such plasmas were investigated according to surface markers, morphology, proliferation, mRNA expression, and the capacity to control T cell proliferation and Treg generation. Results: Interestingly, 57% of aGVHD and 33% of cGVHD plasmas significantly enhanced the immunosuppressive potential of MSCs. The most suppressive MSCs presented altered morphology, and those primed with cGHVD displayed a pronounced overexpression of ICAM-1 on their surface. Furthermore, we observed that the ratio of IFN-γ to IL-10 cytokine levels in the plasma used for MSC priming was significantly correlated with higher suppressive potential and Treg generation induction by primed MSCs, regardless of the clinical status of the donor. Conclusions: This work constitutes an important proof of concept which demonstrates that it is possible to prime MSCs with biological material and also that the cytokine levels in the plasma may affect the MSC immunosuppressive potential, serving as the basis for the development of new therapeutic approaches for the treatment of immune diseases. 2020-10-13T18:11:07Z 2020-10-13T18:11:07Z 2020-04-16 Artigo SILVA-CARVALHO, Amandda Évelin Silva et al. GVHD-derived plasma as a priming strategy of mesenchymal stem cells. Stem Cell Research & Therapy, v. 11, 156, 2020. DOI: https://doi.org/10.1186/s13287-020-01659-x. Disponível em: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01659-x. Acesso em: 13 out. 2020. https://repositorio.unb.br/handle/10482/39539 https://doi.org/10.1186/s13287-020-01659-x Inglês Acesso Aberto © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. application/pdf BMC
institution REPOSITORIO UNB
collection REPOSITORIO UNB
language Inglês
topic Células-tronco mesenquimais
Linfócitos
Doença do enxerto contra hospedeiro
Imunomodulação
spellingShingle Células-tronco mesenquimais
Linfócitos
Doença do enxerto contra hospedeiro
Imunomodulação
Carvalho, Amandda Évelin Silva
Rodrigues, Leane Perim
Schiavinato, Josiane Lilian
Alborghetti, Marcos Rodrigo
Bettarello, Gustavo
Simões, Belinda Pinto
Neves, Francisco de Assis Rocha
Panepucci, Rodrigo Alexandre
Carvalho, Juliana Lott de
Araujo, Felipe Saldanha de
GVHD-derived plasma as a priming strategy of mesenchymal stem cells
description Background: Mesenchymal stem cell (MSC) therapy is an important alternative for GVHD treatment, but a third of patients fail to respond to such therapy. Therefore, strategies to enhance the immunosuppressive potential of MSCs constitute an active area of investigation. Here, we proposed an innovative priming strategy based on the plasma obtained from GVHD patients and tested whether this approach could enhance the immunosuppressive capacity of MSCs. Methods: We obtained the plasma from healthy as well as acute (aGVHD) and chronic (cGVHD) GVHD donors. Plasma samples were characterized according to the TNF-α, IFN-γ, IL-10, IL-1β, IL-12p40, and IL-15 cytokine levels. The MSCs primed with such plasmas were investigated according to surface markers, morphology, proliferation, mRNA expression, and the capacity to control T cell proliferation and Treg generation. Results: Interestingly, 57% of aGVHD and 33% of cGVHD plasmas significantly enhanced the immunosuppressive potential of MSCs. The most suppressive MSCs presented altered morphology, and those primed with cGHVD displayed a pronounced overexpression of ICAM-1 on their surface. Furthermore, we observed that the ratio of IFN-γ to IL-10 cytokine levels in the plasma used for MSC priming was significantly correlated with higher suppressive potential and Treg generation induction by primed MSCs, regardless of the clinical status of the donor. Conclusions: This work constitutes an important proof of concept which demonstrates that it is possible to prime MSCs with biological material and also that the cytokine levels in the plasma may affect the MSC immunosuppressive potential, serving as the basis for the development of new therapeutic approaches for the treatment of immune diseases.
format Artigo
author Carvalho, Amandda Évelin Silva
Rodrigues, Leane Perim
Schiavinato, Josiane Lilian
Alborghetti, Marcos Rodrigo
Bettarello, Gustavo
Simões, Belinda Pinto
Neves, Francisco de Assis Rocha
Panepucci, Rodrigo Alexandre
Carvalho, Juliana Lott de
Araujo, Felipe Saldanha de
author_sort Carvalho, Amandda Évelin Silva
title GVHD-derived plasma as a priming strategy of mesenchymal stem cells
title_short GVHD-derived plasma as a priming strategy of mesenchymal stem cells
title_full GVHD-derived plasma as a priming strategy of mesenchymal stem cells
title_fullStr GVHD-derived plasma as a priming strategy of mesenchymal stem cells
title_full_unstemmed GVHD-derived plasma as a priming strategy of mesenchymal stem cells
title_sort gvhd-derived plasma as a priming strategy of mesenchymal stem cells
publisher BMC
publishDate 2020
url https://repositorio.unb.br/handle/10482/39539
https://doi.org/10.1186/s13287-020-01659-x
_version_ 1680624791621468160
score 13.657419